AMH Provider Manual 2.2 reflects North Carolina’s Integrated Care for Kids (InCK) pilot program expectations and changes that impact Advanced Medical Home Tier 3 contracts with Standard Plans.
Blog Entry List
Brief survey regarding electronic visit verification use in North Carolina
Beginning Dec. 9, 2021, Medicaid and NC Health Choice will cover the Pfizer-BioNTech COVID-19 vaccine booster dose for administration to individuals age 16 and older.
COVID-19 vaccination has been approved for all pediatric patients who meet specific criteria regarding COVID-19.
Effective Dec. 31, 2021, NC Medicaid will end several of the temporary COVID-19 rate increases. Some of the rate increases in effect in December 2021 will be extended – at either current or revised levels - through Jan. 31, 2022.
In order to ensure optimal access to care for NC Medicaid beneficiaries and to support providers during the recent COVID-19 surge, NC Medicaid is extending the Hospital at Home program through March 31, 2022.
The NC Medicaid Electronic Health Record (EHR) Incentive Program is no longer accepting Program Year 2021 attestations.
The seven-part series covers current policies and procedures under the new NC Medicaid Managed Care guidelines.
Standard Plans temporarily extended minimum appeal timeframes to support the transition to NC Medicaid Managed Care.
The Food and Drug Administration and the Advisory Committee on Immunization Practices have authorized COVID-19 boosters for all adults (18 years and older).
The Pre-Admission Screening and Resident Review application has changed its website domain address.
NC Medicaid has extended its deadline to February 2022 to send the renewed waiver application to the Centers for Medicare and Medicaid Services to request approval of the CAP/C waiver for another five years.
The December 2021 NC Medicaid Personal Care Services Public Health Emergency Uniform rates previously released in Special Bulletin COVID-19 #194 are being revised effective Dec. 1, 2021.
Billing guidelines for PADP when billed with HCPCS code J3490.
Effective with date of service Sept. 22, 2021, the Medicaid and NC Health Choice programs cover tisotumab vedotin-tftv for use in the PADP when billed with HCPCS code J9999.